HbA1c level decreases in iron deficiency anemia

Area of Science:

• Endocrinology
• Hematology
• Clinical Chemistry

Background:

• Hemoglobin A1c (HbA1c) is a key marker for glycemic control.
• Conflicting data exist regarding the impact of iron deficiency anemia (IDA) on HbA1c levels.
• This study investigates HbA1c in IDA and the effect of iron treatment in non-diabetic patients.

Purpose of the Study:

• To determine HbA1c levels in patients with IDA compared to healthy controls.
• To assess the impact of iron therapy on HbA1c levels in IDA patients.
• To explore the relationship between anemia severity and HbA1c in non-diabetic individuals.

Main Methods:

• A cohort of 263 non-diabetic patients was studied, including 131 with IDA.
• A control group of 132 healthy individuals was included for comparison.
• HbA1c, hemoglobin, hematocrit, and ferritin levels were measured before and after iron therapy.

Main Results:

• Patients with IDA exhibited significantly lower HbA1c levels (5.4%) than healthy controls (5.9%).
• HbA1c levels decreased with increasing anemia severity.
• Iron therapy led to a slight increase in HbA1c (from 5.4% to 5.5%) and significant improvements in hematological parameters.

Conclusions:

• IDA is associated with lower HbA1c levels in non-diabetic individuals.
• Iron repletion therapy can influence HbA1c levels.
• Clinicians should consider the potential impact of IDA on HbA1c measurements.